|
|
(6 intermediate revisions by the same user not shown) |
Line 26: |
Line 26: |
| | | |
| h11 { | | h11 { |
− | font-family: Montserrat; line-height: 1.25; font-size: 1.5em; padding-bottom: 20px; | + | font-family: Montserrat; line-height: 1.25; font-size: 1.35em; padding-bottom: 20px; |
| } | | } |
| | | |
Line 38: |
Line 38: |
| <div style="padding: 20px 0px; width:95%; margin:auto; font-size:14px;"> | | <div style="padding: 20px 0px; width:95%; margin:auto; font-size:14px;"> |
| | | |
− | <h3 style="font-family: Bavro; font-size: 2.75em; color: #F3557E; text-align: center; padding: 1.5%;">Welcome to the UCopenhagen Poster Page!</h3> | + | <h3 style="font-family: Bavro; font-size: 2.75em; line-height: 1.5; color: #F3557E; text-align: center;">Welcome to the UCopenhagen Poster Page!</h3> |
| <p style="font-family: Avenir, Arial, Helvetica, sans-serif; font-size: 16px; margin-top: 1.5%;">This page looks a little different from the others, as here you'll find the poster we're going to be using at the Jamboree! We hope you enjoy looking through the different sections!</p> | | <p style="font-family: Avenir, Arial, Helvetica, sans-serif; font-size: 16px; margin-top: 1.5%;">This page looks a little different from the others, as here you'll find the poster we're going to be using at the Jamboree! We hope you enjoy looking through the different sections!</p> |
| | | |
Line 106: |
Line 106: |
| </ul> | | </ul> |
| <br> | | <br> |
− | Click through to read about the different biosensor designs in detail.
| + | <img src="https://static.igem.org/mediawiki/2020/0/05/T--UCopenhagen--Poster_quote.pdf"> |
| </div> | | </div> |
| </div> | | </div> |
Line 221: |
Line 221: |
| As the most applicable design required utilization of the yeast pheromone cascade, we had to engineer a novel GPA1 protein that would allow for signal transduction from our designed receptor system. Guided by several iterations of simulations with Rosetta Software Suite, we identified multiple regions suitable for inserting cleavage sites. | | As the most applicable design required utilization of the yeast pheromone cascade, we had to engineer a novel GPA1 protein that would allow for signal transduction from our designed receptor system. Guided by several iterations of simulations with Rosetta Software Suite, we identified multiple regions suitable for inserting cleavage sites. |
| <br> | | <br> |
− | However, the predictions suggested that the post-cleavage protein fragments did not exhibit the properties we expected (fig. 7). Based on these findings, we articulated a refined framework for engineering signal transduction in our biosensor. | + | However, the predictions suggested that the post-cleavage protein fragments did not exhibit the properties we expected, as they gained affinity to the beta subunit instead of losing affinity for it. Based on these findings, we articulated a refined framework for engineering signal transduction in our biosensor. |
| <br><br> | | <br><br> |
− | <img src="https://static.igem.org/mediawiki/2020/8/87/T--UCopenhagen--Poster_m124.png"> | + | <img src="https://static.igem.org/mediawiki/2020/8/83/T--UCopenhagen--Poster_Galpha.png"> |
− | <figcaption style="font-family: Arial, Helvetica, sans-serif; font-size: 12px; line-height: 1.25;text-align: center;margin-top: 1%;"><b>Fig. 7. Change in Gibbs free energy of fragments produced after cleavage of GPA1 mutant m124. </b>The positions of each fragment in the original protein is denoted on the x-axis. Negative values suggest increased affinity to the beta subunit of the yeast G protein. | + | <figcaption style="font-family: Arial, Helvetica, sans-serif; font-size: 12px; line-height: 1.25;text-align: center;margin-top: 1%;"><b>Fig. 7. Structural model of a GPA1 mutant variant with a TEV cleavage site inserted. </b>The red region marks the modified ENLYFQG cleavage sequence. It is located close to the N-terminal α-helix that mediates a significant amount of the binding affinity towards the β-γ complex. |
| </figcaption> | | </figcaption> |
| + | |
| | | |
| | | |
Line 380: |
Line 381: |
| <div class="text"> | | <div class="text"> |
| Human practices were instrumental in both developing the science behind the CIDosis patch, and placing/establishing it in the larger context of healthcare. Both in the initial phases of the project and all throughout the project period, we have engaged with stakeholders and experts that could guide our decisions. | | Human practices were instrumental in both developing the science behind the CIDosis patch, and placing/establishing it in the larger context of healthcare. Both in the initial phases of the project and all throughout the project period, we have engaged with stakeholders and experts that could guide our decisions. |
− | <br><br><br>
| + | <br><br> |
| <h11>Conceptualizing CIDosis</h11><br><br> | | <h11>Conceptualizing CIDosis</h11><br><br> |
| From the conception of the project, our choice to dedicate the patch to measure general inflammation rather than for diagnostic purposes was guided by expert advice from doctors and researchers within the field. Through conversing with specialists in this initial phase of the biosensor design, we decided to make the following wet lab modifications: | | From the conception of the project, our choice to dedicate the patch to measure general inflammation rather than for diagnostic purposes was guided by expert advice from doctors and researchers within the field. Through conversing with specialists in this initial phase of the biosensor design, we decided to make the following wet lab modifications: |
Line 387: |
Line 388: |
| <li>Making a modular design to accommodate the vast number of interleukins that experts deemed could be of clinical interest.</li> | | <li>Making a modular design to accommodate the vast number of interleukins that experts deemed could be of clinical interest.</li> |
| </ul> | | </ul> |
− | <br><br><br> | + | <br><br> |
| <h11>Designing the CIDosis Patch</h11><br><br> | | <h11>Designing the CIDosis Patch</h11><br><br> |
| In total, we engaged with 10 experts ranging from researchers at the University of Copenhagen to doctors in the United States, and received input from 86 CID patients across four interviews and two surveys. While the first survey was aimed at CID patients in general, our second survey specifically targeted Crohn’s and Colitis patients.<br> | | In total, we engaged with 10 experts ranging from researchers at the University of Copenhagen to doctors in the United States, and received input from 86 CID patients across four interviews and two surveys. While the first survey was aimed at CID patients in general, our second survey specifically targeted Crohn’s and Colitis patients.<br> |
Line 473: |
Line 474: |
| <div class="text"> | | <div class="text"> |
| Supervisors: Sotirios Kampranis, Nanna Heinz, Karel Miettinen, Jon Fugl, Nattawat Leelahakorn, Cecilie Cetti Hansen, Iben Egebæk Nikolajsen & Jonas Hansen. | | Supervisors: Sotirios Kampranis, Nanna Heinz, Karel Miettinen, Jon Fugl, Nattawat Leelahakorn, Cecilie Cetti Hansen, Iben Egebæk Nikolajsen & Jonas Hansen. |
| + | <br> |
| <br> | | <br> |
| <br> | | <br> |
Line 491: |
Line 493: |
| [7] - England CG, Ehlerding EB, Cai W. NanoLuc: A Small Luciferase Is Brightening Up the Field of Bioluminescence. Bioconjug Chem. 2016;27(5):1175-1187. doi:10.1021/acs.bioconjchem.6b00112 | | [7] - England CG, Ehlerding EB, Cai W. NanoLuc: A Small Luciferase Is Brightening Up the Field of Bioluminescence. Bioconjug Chem. 2016;27(5):1175-1187. doi:10.1021/acs.bioconjchem.6b00112 |
| <br> | | <br> |
− | | + | <br> |
| + | _________________<br> |
| + | Icons made by <a style="color: black; text-decoration: none;" href="https://www.flaticon.com/authors/freepik" title="Freepik">Freepik</a> from <a style="color: black; text-decoration: none;" href="https://www.flaticon.com/" title="Flaticon">www.flaticon.com</a> |
| | | |
| </div> | | </div> |